Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | LYN | P07948 | 3/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SYK | P43405 | 2/20 | 0.94 |
| ▸ | PLK4 | O00444 | 1/20 | 0.94 |
| ▸ | DDX3X | O00571 | 1/20 | 0.94 |
| ▸ | GAK | O14976 | 1/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.94 |
| ▸ | CA12 | O43570 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29377238 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL726190 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1060852 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL8217 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15632914 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29370699 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1439360 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1440465 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL5004429 | 0.99 | ABL1 (0.97) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859559 | 0.97 | ABL1 (0.94) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-20200030442-A1 | COMBINATION THERAPIES | CAO ZHU ALEXANDER (US) | 2020-01-30 | — | — | US | disclosed |
| EP-2803352-B1 | High dose imatinib tablets | HETERO RESEARCH FOUNDATION (IN) | 2018-08-01 | — | — | EP | disclosed |
| US-20170340733-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-11-30 | — | — | US | disclosed |
| EP-3233918-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| CN-104039324-B | Reduce the compositionss and method of amyloid beta load | 莫德基因有限责任公司 | 2017-03-15 | — | — | CN | disclosed |
| EP-2582689-B1 | NEW POLYMORPHIC FORM OF IMATINIB BASE AND PREPARATION OF SALTS THEREOF | KRKA D D NOVO MESTO (SI) | 2017-03-01 | — | — | EP | disclosed |
| WO-2016100882-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| EP-2803352-A1 | High dose imatinib tablets | Hetero Research Foundation (IN) | 2014-11-19 | — | — | EP | disclosed |
| CN-104039324-A | Compositions and methods for reduction of amyloid-beta load | MODGENE LLC | 2014-09-10 | — | — | CN | disclosed |
| EP-2542548-A1 | PROCESS FOR PREPARATION OF POLYMORPHIC FORM AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS | Kozluk, Tomasz (PL) | 2013-01-09 | — | — | EP | disclosed |
| EP-2491027-A1 | SALTS OF IMATINIB WITH TARTARIC ACIDS | Kozluk, Tomasz (PL) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011157450-A1 | NEW POLYMORPHIC FORM OF IMATINIB BASE AND PREPARATION OF SALTS THEREOF | KRKA, D. D., NOVO MESTO (SI) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011108953-A1 | PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS | KOZLUK TOMASZ (PL) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011049474-A1 | SALTS OF IMATINIB WITH TARTARIC ACIDS | KOZLUK TOMASZ (PL) | 2011-04-28 | — | — | WO | disclosed |
| US-7732601-B2 | Crystalline polymorphs of methanesulfonic acid addition salts of Imatinib | INSTYTUT FARMACEUTYCZNY (PL) | 2010-06-08 | — | — | US | disclosed |
| US-20070197545-A1 | Crystalline Polymorphs Of Methanesulfonic Acid Addition Salts Of Imatinib | INSTYTUT FARMACEUTYCZNY (PL) | 2007-08-23 | — | — | US | disclosed |
| EP-1742933-A2 | CRYSTALLINE METHANESULFONIC ACID ADDITION SALTS OF IMATINIB | INSTYTUT FARMACEUTYCZNY (PL) | 2007-01-17 | — | — | EP | disclosed |
| US-20060223816-A1 | Imatinib mesylate alpha form and production process therefor | CHEMAGIS LTD. (IL) | 2006-10-05 | — | — | US | disclosed |
| WO-2005095379-A2 | CRYSTALLINE METHANESULFONIC ACID ADDITION SALTS OF IMATINIB | INSTYTUT FARMACEUTYCZNY (PL) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030442-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | ABL1 133/4885BCR 366/4885KIT 870/4885 |
| US-20170340733-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | ABL1 133/4885BCR 366/4885KIT 870/4885 |
| US-20070197545-A1 | Crystalline Polymorphs Of Methanesulfonic Acid Addition Salts Of Imatinib | ABL1, PDGFRA, ALK | ABL1 1/4885BCR 8/4885KIT 146/4885 |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | ABL1 304/4885BCR 15/4885KIT 3468/4885 |
| US-20060223816-A1 | Imatinib mesylate alpha form and production process therefor | MET, ABL1, PDGFRA | ABL1 2/4885BCR 272/4885KIT 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.